Morgan Ebert, Managing Editor

Ibrexafungerp (Brexafemme; Scynexis) is now approved for the treatment of vulvovaginal candidiasis and reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC).

Sarah Crafton, MD, details how sentinel lymph node mapping can help identify the stage of uterine cancers and lead to better patient care.

Jeanette Carpenter, MD, MSCI, maternal-fetal medicine specialist at Pediatrix Medical Group, discussed a recently published study regarding pregnant COVID-19 patients who also had disseminated intravascular coagulation (DIC).

In this bonus episode, Nash Moawad, MD, MS, FACOG, FACS, sits down to discuss the recent standardization of Essentials of Minimally Invasive Gynecologic Surgery (EMIGS) training program for minimally invasive gynecologic surgeons and how it's shaping the way this subspecialty delivers care.

This is the first FDA-approved ADC for platinum-resistant disease, according to ImmunoGen.

Tracey Vogel, MD, of the Allegheny Health Network, discusses the organization's new Perinatal Trauma-informed Care Clinic, as well as some useful tips for implementing trauma-informed care into your own practice.

Alyssa Dweck, MD, discusses some recent positive data presented at the 2022 NAMS meeting regarding Clairvee (Bonafide Health) as a potential treatment for vaginal odor.

Houston, Texas, was buzzing with the latest updates in women’s health at the 25th Annual Nurse Practitioners in Women’s Health Premier Women’s Healthcare Conference held from September 29 to October 2, 2022.

Alison Cowan, MD, discusses her predictions for women's health trends in 2023.

Nash Moawad, MD, MS, FACOG, FACS, sits down to discuss the recent standardization of Essentials of Minimally Invasive Gynecologic Surgery (EMIGS) training program for minimally invasive gynecologic surgeons and how it's shaping the way this subspecialty delivers care.

In an exclusive interview, Nash Moawad, MD, MS, FACOG, FACS, discussed the recent implementation of the Essentials of Minimally Invasive Gynecologic Surgery (EMIGS) training program, which helps physicians provide the best care and ensure optimal safety for their patients.

Rebecca Thurston, PhD, sits down to discuss her research presented at the NAMS Annual Meeting on vasomotor symptoms and cardiovascular health.

Rebecca Thurston, PhD, sits down to discuss the latest news from the North American Menopause Society Annual Meeting.

An advisory panel for the US Food and Drug Administration voted 14-1 to withdraw 17α-hydroxyprogesterone caproate (Makena; Covis Pharma) from the market.

History of migraine may be associated with poor sleep in premenopausal and perimenopausal women, according to research presented at the North American Menopause Society Annual Meeting.

Traumatic experiences are associated with lower levels of sex hormones in midlife women, especially those with short sleep, according to research presented at the North American Menopause Society Annual Meeting.

Women with diabetes are more susceptible to early menopause, according to a study presented at the North American Menopause Society Annual Meeting.

Hormone therapy was linked as a potential preventative treatment for adhesive capsulitis in menopausal women, according to a study presented at the North American Menopause Society Annual Meeting.

In a presentation at the North American Menopause Society Annual Meeting, investigators found these signs of menopause are 2 very separate symptoms and have different effects on stress and depression in menopausal women.

In a poster presentation at the North American Menopause Society Annual Meeting, researchers found that diets high in oil, meat, salt, sugar, and coffee contributed to menstrual cramps.

Knowing what is normal and abnormal with the vulvovaginal area is crucial for accurate diagnosis, according to a presentation at the 25th Annual Premier Women's Healthcare Conference held in Houston, Texas.

Nkechi Azie, MD, MBA, FIDSA, vice president of clinical development and medical affairs at SCYNEXIS, discusses the potential FDA approval of ibrexafungerp (Brexafemme; SCYNEXIS) for the prevention of recurrent vulvovaginal candidiasis.

Marina Sirota, PhD, associate professor of pediatrics at the University of California, San Francisco, spoke about the new March of Dimes Prematurity Research Center at UCSF and the impact they hope their research will have on the future of preterm birth.

Marina Sirota, PhD, associate professor of pediatrics at the University of California, San Francisco, spoke about the new March of Dimes Prematurity Research Center at UCSF and the impact they hope their research will have on the future of preterm birth.

Novavax joins the growing list of COVID-19 vaccines including vaccines from Pfizer-BioNTech, Moderna, and Johnson & Johnson’s Janssen

The FDA has approved cetrorelix acetate for injection, a generic version of Cetrotide, for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian stimulation.

Myovant Sciences and Pfizer announces the US Food and Drug Administration has approved Myfembree (relugolix combination tablets) for the once-daily treatment of moderate-to-severe endometriosis-associated pain.

If approved, ibrexafungerp would be the first and only approved therapy for both the treatment of vulvovaginal candidiasis (VVC) and the prevention of recurrent vulvovaginal candidiasis (RVVC).

Genevieve Neal-Perry, MD, PhD, sits down with Contemporary OB/GYN to discuss positive data from a recent phase 3 study evaluating fezolinetant (Astellas) for vasomotor symptoms (VMS).

John Martin, MD, chief medical officer at Butterfly Network, discusses a recent study published in NEJM Evidence, which investigated Butterfly iQ vs a commercial ultrasound machine to detect gestational age.